Prelude Therapeutics Incorporated (NasdaqGS: PRLD)
Health Care · Biotechnology · US
$3.74
-3.86% today · +211.2% 1Y
Prelude Therapeutics Incorporated (NasdaqGS: PRLD) operates in the Biotechnology industry within the Health Care sector. The company is valued at $400.65M and employs 79 people.
Over the last twelve months the share price has gained 211.2%, trading between 1.15 and 6.83.
Tweenvest scores Prelude Therapeutics Incorporated across four factors: quality 37/100, value 75/100. Its strongest factor is value.
PRLD price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $400.65M
- Revenue (TTM)
- $22.42M
- P/E
- —
- EPS
- -0.72
- Dividend yield
- —
- Beta (5Y)
- 0.96
- 52-week high
- $6.83
- 52-week low
- $1.15
- Avg volume (3M)
- —
- Shares outstanding
- 102.99M
- Employees
- 79
- Next earnings
- —
About Prelude Therapeutics Incorporated
Prelude Therapeutics, Inc. is a clinical-stage precision oncology company focused on identifying and developing innovative, targeted cancer treatments for patient populations with unmet medical needs. Its pipeline includes PRT543, currently undergoing Phase 1 clinical evaluation for certain solid tumors and myeloid malignancies. Another asset, PRT811, is also in Phase 1 trials, targeting various solid tumors, notably glioblastoma multiforme. The company is additionally progressing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a powerful and highly kinome-selective CDK9 inhibitor; PRT-SCA2, which is in preclinical development for several genomically selected cancers; PRT3645, a brain-penetrant molecule that precisely and effectively targets CDK4/6; and PRT-K4, another preclinical compound for solid tumors. Founded in 2016, the firm's headquarters are located in Wilmington, Delaware.
- ISIN
- US74065P1012
- Founded
- 2016
- Listed since
- Sep 25, 2020
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AVITA Medical, Inc.NasdaqCM: RCEL | $408.54M | $13.37 | +1.21% |
| Guangdong VTR Bio-Tech Co., Ltd.SZSE: 300381 | $406.47M | CN¥5.67 | -0.35% |
| GI Innovation, Inc.KOSDAQ: A358570 | $405.99M | ₩8,460.00 | -4.08% |
| AP Biosciences, Inc.TPEX: 6945 | $405.68M | NT$133.00 | -2.21% |
| Laekna, Inc.SEHK: 2105 | $400.21M | HK$7.37 | -15.77% |
| Galectin Therapeutics Inc.NasdaqCM: GALT | $397.35M | $3.87 | -1.78% |
| Eikon Therapeutics, Inc.NasdaqGS: EIKN | $393.24M | $7.26 | -2.81% |
| Arcturus Therapeutics Holdings Inc.NasdaqGM: ARCT | $390.53M | $12.61 | -8.22% |
Figures last refreshed Oct 11, 2026.